## ALEXION PHARMACEUTICALS INC

Form 4 July 30, 2014

value

share

\$.0001 per

07/28/2014

July 30, 201	. +								
FORM	14 UNITED	STATES SI	ECURITIES A			NGE CO	MMISSION	OMB AF	PPROVAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).  Washington, D.C. 20549  Washington, D.C. 20549  STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Number: 3235-02 Expires: January 20 Estimated average burden hours per response	
(Print or Type	Responses)								
1. Name and A	Address of Reporting DNARD	Sy	. Issuer Name <b>an</b> mbol LEXION PHA			Is	Relationship of lassuer		
		IN	IC [ALXN]				(Clieck	all applicable	)
(Last)  C/O ALEX PHARMAG KNOTTER	ION CEUTICALS INC	(M 07	Date of Earliest Tonth/Day/Year)  1/28/2014	Transaction		_	_X Director _X Officer (give elow)		Owner or (specify
	(Street)		If Amendment, Ded(Month/Day/Yea	_		A	. Individual or Joi pplicable Line) X_ Form filed by O	ne Reporting Pe	rson
CHESHIRI	E, CT 06410					P	Form filed by Merson	ore than One Re	porting
(City)	(State)	(Zip)	Table I - Non-	Derivative S	Securi	ties Acqui	red, Disposed of,	or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Datany (Month/Day/Y	Code	4. Securitie omr Disposed (Instr. 3, 4 a	d of (D	))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value \$.0001 per share	07/28/2014		M	105,600 (1)	A		1,137,931	D	
Common Stock, par	07/20/2014		G	0.240 (1)	D	\$	1 120 502	D	

S

9,348 (1) D

160.93 1,128,583

(2)

D

## Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common Stock, par value \$.0001 per share	07/28/2014	S	50,737 (1)	D	\$ 162.01 (3)	1,077,846	D
Common Stock, par value \$.0001 per share	07/28/2014	S	34,768 (1)	D	\$ 162.76 (4)	1,043,078	D
Common Stock, par value \$.0001 per share	07/28/2014	S	8,747 (1)	D	\$ 163.81 (5)	1,034,331	D
Common Stock, par value \$.0001 per share	07/28/2014	S	1,000 (1)	D	\$ 164.72 (6)	1,033,331	D
Common Stock, par value \$.0001 per share	07/28/2014	S	1,000 (1)	D	\$ 166.12 (7)	1,032,331	D
Common Stock, par value \$.0001 per share	07/29/2014	M	1,200 (1)	A	\$ 17.65	1,033,531	D
Common Stock, par value \$.0001 per share	07/29/2014	S	1,200 (1)	D	\$ 164.93 (8)	1,032,331	D
Common Stock, par value \$.0001 per share	07/30/2014	M	20,489 (1)	A	\$ 17.65	1,052,820	D
Common Stock, par value \$.0001 per share	07/30/2014	S	13,679 (1)	D	\$ 165.18 (8)	1,039,141	D
	07/30/2014	S	4,010 (1)	D		1,035,131	D

## Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common Stock, par value \$.0001 per share			\$ 166.42 (9)	
Common Stock, par value 07/30/2014 \$.0001 per share	S	2,800 (1) D	\$ 167.14 1,032,331 (10)	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Secur Secur Acqu Dispo		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Option to Purchase Common Stock	\$ 17.65	07/28/2014		M		105,600 (1)	04/09/2008	01/09/2018	Common Stock	105,60
Option to Purchase Common Stock	\$ 17.65	07/29/2014		M		1,200 (1)	04/09/2008	01/09/2018	Common Stock	1,200
Option to Purchase Common Stock	\$ 17.65	07/30/2014		M		20,489	04/09/2008	01/09/2018	Common Stock	20,48

# **Reporting Owners**

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				

Reporting Owners 3

#### Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

BELL LEONARD
C/O ALEXION PHARMACEUTICALS INC
352 KNOTTER DRIVE
CHESHIRE, CT 06410

## **Signatures**

/s/ Michael Greco Attorney-in-Fact

07/30/2014

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$160.42 \$161.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$161.42 \$162.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$162.42 \$163.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$163.43 \$164.43. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$164.44 \$165.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$165.84 \$166.84. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$164.90 \$165.90. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$166.91 \$167.91. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$166.98 \$167.98. The price reported in (10) this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4